Germany Archives

News and Trends 6 May 2015

Flagship Ventures recruited a Dream Team composed of Astra Zeneca, Bayer and Nestlé

AstraZeneca, Bayer and Nestlé have entered Flagship Ventures’ ranks. The three big-shots will share their know how to support Flagship’s VentureLabs, its start-up incubator. Yet another victory for the American leading VC company that recently banked €478M. On March 26th, Flagship Ventures established its own personal record, putting together €478M in new funds. As Noubar Afeyan, […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

thrombosis bayer healthcare isis pharmaceuticals

News and Trends 5 May 2015

Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

Isis Pharmaceuticals and Bayer HealthCare will develop and commercialize ISIS-FXIRx for the prevention of thrombosis. The German Pharma will provide up to €139M to Isis, including an up-front payment of €89.6M. Under the terms of the agreement, Isis is eligible to receive up to €139M in near-term payments, including an immediate €89.6M up-front payment and […]

May 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 May 2015

Natural Killer therapies for Cancer: a Fast-Evolving field

Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors, that specifically regulate the activity of the immune system, are attracting the attention of several small startups and more than a few big Pharmas. The immune system includes a set of body defenses, that fight foreign forms. But external bodies aren’t […]

May 5, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Sygnis on the way to conquer the UK Life Sciences market

Sygnis signed a distribution agreement with Cambridge Bioscience for the commercialization of its proprietary product portfolio in the UK and Ireland. This is a significant expansion of product roll-out into one of the most important life science markets in Europe. Under the terms and conditions of the agreement, Cambridge Bioscience will promote, market, sell and […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

Cytena greets €1.1M of Seed Capital

Cytena and its cy-Clone device to separate single cells received €1.1M from a consortium made up of a private investor and the High-Tech Gründerfonds (HTGF). Cytena will use this capital injection primarily to launch its product and to expand its marketing and distribution activities. The cy-Clone, cytena’s newest innovation, is a laboratory device that enables the […]

April 29, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Apr 2015

Are personalized treatments for lung cancer underutilized?

Results from a new global survey of lung cancer oncologists have shown that, despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for Epidermal Growth Factor Receptor mutations (EGFR), a significant number of those tested were not receiving personalized treatments for their cancer type and mutation subtype. The survey, with […]

April 23, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

OncoBEAM blood test arrives to Europe

Sysmex Inostics have signed an exclusive distributor agreement with IndivuTest, and its parent company Indivumed, a cancer research company focused on the development of individualized cancer diagnostics and therapies. This collaboration will offer Sysmex’s OncoBEAM services throughout Germany, Austria and Switzerland. IndivuTest will be responsible for commercial and sample logistics, with all testing being performed […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 Apr 2015

GATC backs Molecular Health’s tumour profiling system

GATC Biotech has signed a commercial agreement with Molecular Health to market and support Molecular Health’s state-of-the-art system for tumour profiling. Under this agreement, GATC Biotech will make the company’s analytical software, TreatmentMAP, available to patients worldwide. Every cancer is unique, which is why cancer patients respond differently to cancer treatments. Scientific discoveries and technological […]

April 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Apr 2015

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

Merck Serono appointed Dr. Alise Reicin as Senior Vice President, Head of Global Clinical Development. The appointment is yet another example of Merck’s clear interest in oncology and immunology, two fields in which Dr. Reicin expertised. Dr. Reicin will also bring extensive research and early/late clinical development expertise to Merck Serono. In her role as […]

April 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

The first-in-human Phase I trial for a treatment against glaucoma core

Isarna Therapeutics has initiated Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2) to treat advanced glaucoma. This first-in-human Phase I trial, conducted at the University Hospitals of Mainz and Tuebingen, Germany, is designed to evaluate the safety and long-term tolerability of ISTH0036 in patients with advanced glaucoma […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Yesterday, the company announced a €94M investment in its Berkeley (California) manufacturing site to build a product testing facility that will support the next generation of treatments for patients with hemophilia A. David […]

April 16, 2015 - 2 minutesmins - By Joachim Eeckhout

final sterilization proteins solution sanofi pasteur

News and Trends 16 Apr 2015

The challenge of terminal sterilization of Proteins

The production of biologicals is an important challenge for the industry. Today, very often, the only way to have a sterile final product is to, first, use sterile components and then, launch the production in a fully aseptic manufacturing facility. What if we could terminally sterilize the protein-based outcome once produced? More and more biologicals are brought to the market, […]

April 16, 2015 - 3 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Germany

Flagship Ventures recruited a Dream Team composed of Astra Zeneca, Bayer and Nestlé

Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

Natural Killer therapies for Cancer: a Fast-Evolving field

Sygnis on the way to conquer the UK Life Sciences market

Cytena greets €1.1M of Seed Capital

Are personalized treatments for lung cancer underutilized?

OncoBEAM blood test arrives to Europe

GATC backs Molecular Health’s tumour profiling system

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

The first-in-human Phase I trial for a treatment against glaucoma core

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

The challenge of terminal sterilization of Proteins

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!